<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00426582</url>
  </required_header>
  <id_info>
    <org_study_id>CEPO906A2105</org_study_id>
    <nct_id>NCT00426582</nct_id>
  </id_info>
  <brief_title>Combination Trial of Patupilone and Carboplatin in Adult Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase Ib, Multicenter, Open-label, Dose-finding Study of Patupilone Administered Intravenously Every 3 Weeks in Combination With Carboplatin AUC 6 in Adult Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will evaluate the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of&#xD;
      patupilone combined with carboplatin in adult patients with advanced solid tumors who&#xD;
      progressed despite standard therapy or for whom no standard therapy exists or who might&#xD;
      benefit from treatment with carboplatin&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of patupilone in combination with carboplatin (AUC 6)</measure>
    <time_frame>Every 3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of patupilone combined with carboplatin assessed by adverse events, serious adverse events, laboratory values and physical examinations</measure>
    <time_frame>Every 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (complete and partial response; CR + PR) according to RECIST (response evaluation criteria in solid tumors)</measure>
    <time_frame>Every 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression (TTP), duration of overall response, duration of stable disease and time to overall response</measure>
    <time_frame>Every 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of patupilone combined with carboplatin</measure>
    <time_frame>First 6 weeks (cycle 1 &amp; 2 only)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between pharmacokinetics and clinical outcome</measure>
    <time_frame>Every 6 weeks during cycle 1 &amp; cycle 2</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Patupilone only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle 1 patupilone alone Cycle 2 and onward patupilone and carboplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carboplatin alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cycle 1 Carboplatin alone Cycle 2 and onward patuilone and carboplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Patupilone</intervention_name>
    <arm_group_label>Carboplatin alone</arm_group_label>
    <arm_group_label>Patupilone only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed advanced solid tumors who have progressed&#xD;
             despite standard therapy, or for whom no standard therapy exists, or who might benefit&#xD;
             from treatment with carboplatin&#xD;
&#xD;
          -  A minimum of 4 weeks since the last treatment with chemotherapy&#xD;
&#xD;
          -  WHO Performance Status 0 (able to carry out all normal activity without restriction)&#xD;
             or 1 (restricted in physically strenuous activity but ambulatory and able to carry out&#xD;
             work)&#xD;
&#xD;
          -  Age â‰¥ 18&#xD;
&#xD;
          -  Adequate hematological parameters&#xD;
&#xD;
          -  No major impairment of renal or hepatic function&#xD;
&#xD;
          -  Written informed consent obtained&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Major surgery less than 4 weeks prior to study entry and/or not fully recovered from&#xD;
             surgery&#xD;
&#xD;
          -  Chemotherapy or investigational compound less than 4 weeks prior to study entry, or&#xD;
             planned while participating in the study&#xD;
&#xD;
          -  Prior administration of an epothilone&#xD;
&#xD;
          -  Hypersensitivity to carboplatin. Patients resistant to carboplatin are not recommended&#xD;
             to enter the trial&#xD;
&#xD;
          -  Radiotherapy (RT) less than 4 weeks prior to study entry (except for palliative&#xD;
             therapy of distant metastases), or planned RT while participating in the study&#xD;
&#xD;
          -  Diarrhea within 7 days prior to start of treatment. Unresolved bowel obstruction&#xD;
&#xD;
          -  Peripheral neuropathy &gt; Grade 1 (mild)&#xD;
&#xD;
          -  Symptomatic brain metastases&#xD;
&#xD;
          -  Colostomy&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmeceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Norwalk Hospital</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <zip>06856</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associates in Oncology</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wertz Clinical Cancer Center (Wayne State University)</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center (Washington University School of Medicine)</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110-1093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Research and Treatment Center (University of New Mexico)</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=5244</url>
    <description>Results can be found for CEPO906A2105 on the Novartis Clinical Trial Results Website</description>
  </link>
  <verification_date>March 2011</verification_date>
  <study_first_submitted>January 24, 2007</study_first_submitted>
  <study_first_submitted_qc>January 24, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2007</study_first_posted>
  <last_update_submitted>December 6, 2020</last_update_submitted>
  <last_update_submitted_qc>December 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2020</last_update_posted>
  <responsible_party>
    <name_title>External Affairs</name_title>
    <organization>Novartis Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>maximum tolerated dose</keyword>
  <keyword>dose-limiting toxicity</keyword>
  <keyword>patupilone</keyword>
  <keyword>carboplatin</keyword>
  <keyword>pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epothilone B</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

